Dual targeting of EGFR: ready for prime time?
Details
Publication Year 2016,Volume 5,Issue #Suppl 1,Page S18-S21
Journal Title
Translational Cancer Research
Publication Type
Journal Article
Abstract
Monoclonal antibodies against the Epidermal Growth Factor Receptor (EGFR) are accepted therapies in number of cancer types including colorectal cancer (CRC), and head and neck cancer.
Publisher
AME Publishing Company
Research Division(s)
Structural Biology
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2017-05-26 03:48:49
Last Modified: 2020-04-07 02:34:58
An error has occurred. This application may no longer respond until reloaded. Reload 🗙